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It is well established that after metastatic cancer cells escape the primary tumour and enter the
circulation, their interactions with microvascular endothelium of a target organ constitute an
essential rate-limiting step in haematogenous cancer metastasis. However, the physiological and
biochemical processes supporting neoplastic cell arrest and retention in the microcirculation
are still poorly understood. In this study, we present experimental evidence that microvascular
endothelium of metastasis-prone tissues undergoes activation in response to desialylated
cancer-associated carbohydrate structures such as Thomsen–Friedenreich (TF) antigen (Galβ1–
3GalNAc) expressed on circulating glycoproteins and neoplastic cells. The metastasis-associated
endothelium activation, manifested by marked increase in endothelial cell surface galectin-3
expression, causes gradual decrease in cancer cell velocities (from 72 × 102 ± 33 × 102 µm s−1
to 7.6 × 102 ± 1.9 × 102 µm s−1, mean ± S.D.) accompanied by a corresponding increase in the
percentage of rolling cells (from 3.3% ± 1.2% to 24.3% ± 3.6%, mean ± S.D.), and results
in human breast and prostate carcinoma cell arrest and retention in the microvasculature.
This process, which could be of high importance in haematogenous cancer metastasis, was
inhibited efficiently by an anti-TF antigen function-blocking antibody. Carbohydrate-mediated
endothelial activation could be a process of physiological significance as it probably occurs in
the interactions between a variety of circulating constituents and the vessel wall.
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Metastatic tumour cell adhesion to microvascular
endothelium of a target organ represents an essential
early step in haematogenous cancer metastasis (Orr &
Wang, 2001). The molecular and cellular mechanisms
underpinning this process remain poorly understood.
For example, in inflammation, leucocyte–endothelium
adhesion requires endothelial activation by inflammatory
cytokines such as tumour necrosis factor α (TNFα)
or interleukin-1β (IL-1β), resulting in a cell surface
mobilization of endothelial selectins (reviewed in McEver,
1997), and a coordinated set of highly orchestrated selectin
interactions with their cognate carbohydrate ligands,
mostly Lewis(x), sialyl-Lewis(x) and sialyl-Lewis(a) core
2 oligosaccharides (Butcher, 1991; Lawrence & Springer,
1991; McEver, 1997), mediating leucocyte rolling and
adhesion (Lawrence & Springer, 1991; McEver, 1997).
V.H.H. and V.V.G. share senior authorship.
Perhaps with the exception of colon carcinoma (Krause &
Turner, 1999), such an activation scheme fails to enhance
neoplastic cell adhesion to the endothelium (Cooper
et al. 2002). Moreover, in a related study, Satoh et al.
(1998) demonstrated that multiple prostate carcinoma cell
lines, expressing sialyl-Lewis(x), the carbohydrate epitope
recognized by endothelial selectins supporting leucocyte
rolling, lack selectin-dependent adhesion.
These observations suggest that leucocyte and
metastatic tumour cell adhesion to microvascular
endothelium are driven by different molecular
mechanisms. Indeed, recent results demonstrate
that breast and prostate cancer cell adhesion to the
microvascular endothelium of metastasis-prone tissues
is mediated largely by interactions between cancer-
associated TF glycoantigen (Galβ1–3GalNAc) presented
on neoplastic cells and endothelium-expressed β-
galactoside binding lectin galectin-3 (Lehr & Pienta,
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1998; Glinsky et al. 2000, 2001; Nangia-Makker et al.
2002; Khaldoyanidi et al. 2003). However, similarly to
selectins, galectin-3 is often localized intracellularly
(Ellerhorst et al. 1999; Glinsky et al. 2001). To
participate in cell-to-cell adhesive interactions, this
carbohydrate-binding protein must be translocated to
the endothelial cell surface. Recently, based on the ability
of asialofetuin (a glycoprotein expressing multiple TF
antigen epitopes) and TF antigen–human serum albumin
conjugate (TF–HSA) to increase galectin-3 cell surface
expression on cultured endothelial cells (Glinsky et al.
2001), we suggested that desialylated cancer-associated
carbohydrate structures can induce such translocation,
thereby modifying endothelial cell adhesive properties
and priming them for binding metastatic cancer cells
(Glinsky et al. 2001).
In this report, we present in vitro and ex vivo
experimental evidence of microvascular endothelium
activation manifested by a marked increase in galectin-
3 cell surface expression promoting metastatic breast
and prostate carcinoma cell adhesion to the endothelia
of intact well-differentiated microvessels. In contrast
to leucocyte adhesion, this activation occurs in a
non-cytokine-mediated manner and is induced by
cancer-associated carbohydrate structures (TF antigen
disaccharide) expressed on metastatic tumour cells
(direct activation) or circulating glycoproteins (indirect
activation), which could often be found in serum
of patients with adenocarcinomas of different origin
(Bresalier et al. 1996; Duffy, 1999). Given the efficient
inhibition of this process by anti-TF antigen monoclonal
antibody, such activation could be an important target for
developing new approaches to preventing and controlling
haematogenous breast and prostate cancer metastasis.
Methods
Antibodies, chemicals, and reagents
The TIB-166 hybridoma, producing rat anti-galectin-3
monoclonal antibody (mAb) was obtained from ATCC
(Manassas, VA, USA). The JAA-F11 hybridoma producing
anti-TF antigen mAb (Rittenhouse-Diakun et al. 1998) was
from Dr K. Rittenhouse-Olson (State University of New
York, Buffalo, NY, USA). All other chemicals and reagents,
unless otherwise specified, were from Sigma (St Louis, MO,
USA).
Cell lines and cultures
The highly metastatic MDA-MB-435 and non-metastatic
MDA-MB-468 human breast carcinoma cell lines were
provided by Dr J. E. Price (M.D. Anderson Cancer Center,
Houston, TX, USA). The DU-145 metastatic human
prostate carcinoma cells were from ATCC. The RPMI-
1640 medium supplemented with l-glutamine, 10% fetal
bovine serum (FBS), sodium pyruvate and non-essential
amino acids was used for tumour cell lines. For adhesion
experiments, cancer cells were prelabelled for 5 min with
a 3 µg/ml solution of acridine orange in RPMI-1640
medium, rinsed three times with serum free RPMI-1640
medium, dissociated from plastic using a non-enzymatic
cell dissociation reagent (Sigma), and pipetted to produce
a single cell suspension.
Owing to its rapidity and simplicity, labelling neoplastic
cells with acridine orange represents a valuable method
of choice for our experiments, in which freshly prepared
single cell suspension is required for each round
(i.e. every 30 min). Abbitt et al. (2000) reported
recently that acridine orange could modify the adhesion
behaviour of neutrophils by inducing β2-integrin
(CD18) expression. However, our previous studies,
involving parallel experiments with acridine orange-
and dioctadecyl-tetramethylindocarbocyanine (DiIC18)-
labelled breast and prostate carcinoma cells (Glinsky
et al. 2000, 2001), did not reveal any significant effects
of acridine orange labelling on malignant cell adhesive
behaviour. One possible explanation for this could be
that β2-integrin does not play a major role in cancer–
endothelial cell adhesion. Blocking CD18 function caused
only marginal (< 20%) inhibition of prostate cancer cell
adhesion to bone marrow endothelium in a static adhesion
assay (Lehr & Pienta, 1998), and failed completely to
inhibit breast carcinoma cell adhesion to endothelial cells
in flow (Khaldoyanidi et al. 2003). Another explanation
could be that, as the neoplastic cells are labelled with
acridine orange for each round immediately prior to
preparation and perfusion of the single cell suspension
through the microvasculature for 30 min, the time
course is not of sufficient length for acridine orange to
alter significantly transcriptional processes, which could
lead to appreciable changes in the protein expression
levels.
Nevertheless, we performed additional parallel flow
chamber experiments to compare rolling responses of
non-labelled and acridine orange-labelled MDA-MB-435
cells perfused over a monolayer of HBME-1 human bone
marrow endothelial cells. The results of these experiments
demonstrated that acridine orange did not modify
significantly MDA-MB-435 human breast carcinoma cell
rolling on HBME-1 monolayers. Specifically, at the wall
shear stress of 2.4 dyn cm−2, the rolling flux of non-labelled
and acridine orange-labelled MDA-MB-435 cells differed
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by <5 % (27.7% ± 2.6%, mean ± s.d., n = 358; and 32.1%
± 9.5%, mean ± s.d., n = 500, respectively).
The human bone marrow endothelial cell line
HBMEC-60, immortalized using the amphotrophic
helper-free retrovirus pLXSN16 E6/E7 (Rood et al. 2000),
was provided by Dr C.E. van der Schoot (University
of Amsterdam, Amsterdam, The Netherlands). The
HBMEC-60 cells were shown to maintain their normal
phenotype and adhesive properties, specifically the ability
to bind haematopoietic progenitor cells (Rood et al. 2000).
The development of the HBME-1 human bone marrow
endothelial cell line, immortalized using SV40 large T
antigen, was as previously described (Lehr & Pienta, 1998).
The basal Medium 200 (Cascade Biologics, Portland, OR,
USA) supplemented with 20% FBS and low serum growth
supplement containing hydrocortisone, human fibroblast
growth factor, heparin and human epidermal growth
factor was used for culturing HBMEC-60 and HBME-1.
Perfused porcine dura mater model
Porcine dura mater was used in adhesion experiments
as described in detail elsewhere (Glinskii et al. 2003a,b).
Briefly, dura mater corresponding to one hemisphere
was collected from mature male (for prostate cancer
experiments, n = 12) or female (for breast cancer
experiments, n = 14) Yucatan miniature swine (Charles
River, ME, USA) within 30 min of death. The animals
were killed in accordance with the University of Missouri
approved animal care protocol. Dura mater was dissected
and flattened on to a Sylgard-coated 100 mm dish. A major
branch of the median meningeal artery (typically 300–
500 µm i.d.) was cannulated, and dura vasculature was
perfused at 15 µl min−1 first with Krebs physiological
salt supplemented with 1.0 mg ml−1 porcine serum
albumin for 20 min, then with vessel-labelling solution
(0.3 µg ml−1 acridine orange in RPMI-1640 supplemented
with 10% FBS and 1.0 mg ml−1 porcine albumin)
for an additional 40 min. In selected experiments,
asialofetuin or fetuin were added to the vessel labelling
solution at 1.0 mg ml−1 final concentration. Asialofetuin
is a glycoprotein carrying multiple desialylated TF
antigen moieties, whereas fetuin differs from asialofetuin
only in that the TF antigen moieties are masked
covalently with sialic (neuraminic) acid. In function
inhibition experiments, undiluted supernatant from JAA-
F11 hybridoma, producing function-blocking antibody
against TF antigen, was used instead of RPMI-1640. In
addition, to determine the contribution of shear forces,
in selected experiments after labelling microvessels with
acridine orange, dura mater was preperfused at the above
rate for 2 h prior to tumour cell injection.
Immediately prior to injection, cancer cells were
prelabelled for 5 min with 3 µg ml−1 acridine orange
solution in RPMI-1640 medium, rinsed three times,
dissociated from plastic, pipetted to produce a single
cell suspension, filtered through a 20 µm nylon mesh
to remove any remaining cell clumps, and adjusted to
contain 5 × 104 cells ml−1. A fresh tumour cell suspension
in perfusion buffer (RPMI-1640 supplemented with 10%
FBS and 1.0 mg ml−1 porcine serum albumin) was
prepared for each 30 min round and injected into the
system using an inline chromatography injector with all-
Teflon wetted parts (Rheodyne Model 50200, Rheodyne,
CA, USA) equipped with a 500 µl loop. Cancer cell
interactions with dura microvasculature were monitored
at several predetermined observation points over 80–
100 µm i.d. microvessels (minimum of eight observation
points per experiment, i.e. two observation points per
round) and video recorded at 30 frames per second using a
fluorescence video microscopy system based on a Laborlux
8 microscope (Leitz Wetzlar, Germany) equipped with
75 W xenon lamp and a high sensitivity CCD video camera
(COHU Inc., San Diego, CA, USA). For subsequent frame-
by-frame analysis, the recorded analog video images were
digitized using a media converter DVMC-DA2 (Sony,
Japan) and Adobe Premier 6 software (Adobe Systems Inc.,
San Jose, CA, USA).
Data analysis and interpretation
An offline frame-by-frame analysis was used to determine
cancer cell velocities within perfused dura mater
microvasculature. Based on velocity measurements and
adhesion behaviour, we divided circulating malignant
cells into the following categories: non-interacting/freely
floating cells, interacting/rolling cells, slow rolling cells,
and stably adherent cells.
In our previous studies, employing the same
experimental conditions (Glinskii et al. 2003a,b), we
determined a velocity limit for distinguishing between
non-interacting/floating and interacting/rolling cells
within 80–100 µm arterioles of 2000 µm s−1. This
determination was made based solely on experimental
results, as we observed neoplastic cells moving at velocities
as high as 1500– 2000 µm s−1 engaging momentarily
in stable adhesive interactions with microvessel walls
(Fig. 1). However, as early as in 1985–1991, in a
series of fundamental works on leucocyte–endothelial
interactions (Gaehtgens et al. 1985; Ley et al. 1991; Ley &
Gaehtgens, 1991), Ley and Gaehtgens introduced the term
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critical velocity (V crit), defining a minimal velocity that a
freely flowing cell can assume under given experimental
conditions and developed a formula
Vcrit = VCL × ε × (2 − ε)
where V CL is the velocity of a cell floating at the centreline,
and e is the ratio of a cell diameter to the vessel diameter.
Any cell travelling at a velocity below V crit is likely to
be retarded by adhesive interactions with vascular wall
and should be designated as rolling (Ley & Gaehtgens,
1991). Using such a criterion allows for unambiguous
identification of cells interacting with vessel wall even in
the absence of information on their relative radial position
(Ley et al. 1991).
We have used the formula developed by Ley & Gaehtgens
(1991) to calculate V crit for our experimental conditions,
i.e. for tumour cells travelling within 80–100 µm arterioles
perfused at the physiological rate. For these calculations,
we assumed the average tumour cell velocity of 7200 µm
s−1 at the beginning of the experiment before endothelium
activation occurred (see Results and discussion) as V CL, the
average tumour cell diameter to be 15 µm and the average
vessel diameter to be 90 µm. The resulting calculated V crit
value of 2200 µm s−1 appears to be in good agreement
with our velocity limit of 2000 µm s−1 for identifying
interacting/rolling cancer cells within 80–100 µm
arterioles established experimentally.
To distinguish a subpopulation of cancer cells
interacting with endothelium more specifically, we used
several additional velocity and adhesion behaviour criteria
to identify slowly rolling tumour cells: (1) clearly visible
rolling; (2) frequent stoppages, interruptions and changes
in velocity; (3) deviations from a straight-line movement
in a zigzag manner; and (4) rolling velocity below 600 µm
s−1. The last determination was made based on the fact
that mean blood velocities and corresponding wall shear
rates in arterioles are about double those in post-capillary
venules of the same size (Ley & Gaehtgens, 1991). As
velocities up to 300 µm s−1 were described for leucocytes
rolling in post-capillary venules (Ley & Gaehtgens, 1991),
we established a 600 µm s−1 velocity limit for identifying
cancer cells slowly rolling in 80–100 µm arterioles. In this
report, we will use the term interacting/rolling cells to refer
to the population of neoplastic cells travelling at velocities
below V crit, whereas the term rolling will be used to refer
to the subset of slowly rolling cells.
In contrast to cancer cells transiently interacting with
vessel walls and designated as interacting/rolling (rapidly
rolling) and slowly rolling, some neoplastic cells were
engaged in more stable adhesive interactions and remained
stationary for a prolonged period of time (>1 min). For
the purpose of this study, such cells were designated as
stably adherent.
Analysis of cell surface galectin-3 expression
The ex vivo immunofluorescence analysis of intravascular
cell surface galectin-3 expression was performed using
TIB-166 anti-galectin-3 antibody. After completion of the
cancer cell adhesion experiment or asialofetuin perfusion,
dura mater was perfused for 30 min with anti-galectin-3
mAb diluted 1 : 10, followed by a 30 min wash, 30 min
perfusion with 10.0 µg ml−1 solution of Alexa Fluor 594-
labelled goat anti-rat IgG (Molecular Probes, Eugene, OR,
USA), and an additional 30 min wash. The in vitro analysis
of cell surface galectin-3 expression on non-fixed and non-
permeabilized cultured HBMEC was performed exactly as
previously described (Glinsky et al. 2001, 2003).
Figure 1. Stable adhesion of a rapidly rolling metastatic cancer
cell
The MDA-MB-435 human breast carcinoma cell travelling at 1560 µm
s−1 (A) momentarily stops, (B) slightly rolls, (C) becomes stably
attached to a vascular wall (D) and remains stationary until the end of
the observation period (E). Numbers in boxes show time code
generator readings corresponding to each frame in hours, minutes,
seconds, and frame numbers (30 frames s−1) presented as
hh:mm:ss:ff. The differences in time between images shown are: 0.13
s (between A and B), 0.67 s (between B and C), 2.37 s (between C and
D) and over 17 min (between D and E). Scale bar, 200 µm shown in A.
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Results
The percentage of cancer cells interacting with
microvascular endothelium increases over time as
a function of tumour cell–vascular wall collisions
Many important results regarding tumour–endothelial
cell interactions have previously been obtained in vitro
using cultured endothelial cells. However, as endothelial
cell properties depend to a large extent on their organ-
specific microenvironment (Ruoslahti & Rajotte, 2000)
and preserving original microenvironment and temporal
dynamics is crucial for obtaining the most accurate and
reliable data (Padera et al. 2002), we investigated the
kinetics of breast and prostate carcinoma cell adhesive
interactions with intact well-differentiated microvessels
of dura mater, a tissue often targeted by haematogenous
cancer metastasis (Rubin et al. 2000). In these experiments,
we analysed tumour cell velocities and percentage
of interacting/rolling cancer cells within dura mater
microvasculature perfused at the physiological flow rate
(15 µl min−1) with a single cell suspension (5 × 104 cells
ml−1) of fluorescently labelled neoplastic cells (metastatic
DU-145 prostate carcinoma or MDA-MB-435 breast
carcinoma, and non-metastatic MDA-MB-468 breast
carcinoma) using experimental techniques developed
recently in our laboratory (Glinskii et al. 2003a,b). As
we reported, in contrast to leucocyte adhesion, that the
vast majority of cancer cell adhesive interactions with
microvessels occur in precapillary arterioles (Glinskii et al.
2003), we specifically focused on analysing tumour cell
adhesion kinetics within an arterial compartment of
dura mater microvasculature. Neoplastic cell intravascular
adhesive behaviour was monitored and video recorded at
several predetermined observation points over 80–100µm
i.d. arterioles, and 500 µl of freshly prepared single cell
suspension was injected every 30 min.
Intriguingly, at the beginning of the experiments,
perfused metastatic cells moved at high velocities (72 ×
102 ± 33 × 102 µm s−1, mean ± s.d.). At this time,
only a small fraction (3.3% ± 1.2%, mean ± s.d. of
neoplastic cells exhibited slow rolling behaviour and none
engaged into stable adhesion either within immediately
observed microvessels or within perfused vascular tree.
However, as the experiments progressed, we observed a
gradual decrease in tumour cell velocity over time with
each consecutive injection (Fig. 2A). Subsequently, even
though the perfusion rate was kept constant, toward the
fourth round of experiments (1.5–2 h of perfusion) the
average tumour cell velocity decreased almost 10-fold (7.6
× 102 ± 1.9 × 102 µm s−1, mean ± s.d.) compared with
the first round and 100% of cells observed travelled at
velocities below V crit (Fig. 2A).
The observed reduction in tumour cell velocity below
V crit probably reflects their displacement toward blood
vessel walls and increased adhesive interactions with
microvascular endothelium. Indeed, a gradual decrease
in metastatic cell velocity was accompanied by a
corresponding gradual increase in the percentage of
slowly rolling cells (Fig. 2B) from 3.3% ± 1.2% to
24.3% ± 3.6% (mean ± s.d.; by the fourth round of
the experiment, abundant tumour cell interactions with
dura microvasculature were observed along with multiple
neoplastic cells stably adhered in precapillary arterioles
and capillaries.
We observed consistently this pattern of dynamic
changes in metastatic cell–microvascular endothelium
adhesion kinetics in both prostate and breast carcinoma
Figure 2. Gradual increase in malignant cell adhesive
interactions with microvascular endothelium over time
A, gradual decrease in velocities of DU-145 metastatic prostate
carcinoma cells perfused at constant physiological rate (15 µl min−1).
Open squares represent individual values; filled circles represent
average velocity; shaded area, ± average deviation; each round
corresponds to 30 min of perfusion. Bars show combined results of
three independent experiments presented as mean + S.D. B, gradual
increase in the proportion of rolling tumour cells over the course of an
adhesion experiment (mean + S.D.).
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cell experiments on 14 dura mater preparations (eight
males, six females, respectively). These results imply
that adhesive properties of either endothelial or cancer
cells (or both) undergo significant modification over the
course of an experiment. However, as the single cell
suspension of tumour cells was prepared freshly prior to
each injection, i.e. every 30 min, the observed changes
in kinetics of metastatic cell interactions with perfused
microvasculature probably reflect changes in endothelial
cell adhesiveness. In other words, upon perfusion
with metastatic cancer cells, microvascular endothelium
undergoes activation promoting malignant cell rolling
and retention in the target organ microvasculature.
Furthermore, this metastasis-associated endothelium
activation appears to be mediated not by shear force, but
rather by tumour cell collisions with vascular walls, as
preperfusing microvessels for the same time period (2 h)
in the absence of cancer cells did not modify tumour
cell–microvascular endothelium adhesion kinetics (data
not shown). This, in turn, suggests the existence of one
or more factors responsible for such activation presented
on malignant cell outer surfaces. Recently, based on the
ability of cancer-associated TF glycoantigen expressed
on asialofetuin and TF antigen–human serum albumin
conjugate to increase galectin-3 cell surface expression on
cultured endothelial cells, we suggested that TF antigen
expressed on neoplastic cells and circulating tumour-
secreted glycoproteins could potentially perform such
function (Glinsky et al. 2001). We next investigated
whether TF antigen is indeed responsible for changes
in kinetics of metastatic cell interactions with dura
microvessels.
Cancer cells and asialofetuin activate microvascular
endothelium in a TF antigen-dependent manner
We have used several independent approaches to address
this question. First, we investigated whether non-
metastatic MDA-MB-468 breast carcinoma cells, deficient
in TF antigen expression (Khaldoyanidi et al. 2003), would
exhibit similar intravascular adhesion kinetics as highly
metastatic DU-145 (Fig. 2A) and MDA-MB-435 (Fig. 3A)
cells. The results of these experiments demonstrated that,
in contrast to highly metastatic cells expressing significant
TF antigen levels (Glinsky et al. 2000, 2001), MDA-MB-
468 neither exhibited a decrease in velocity (Fig. 3A) nor
engaged into adhesive interactions with dura microvessels.
Next, we studied the effects of function blocking anti-TF
antigen antibody on adhesion kinetics of highly metastatic
MDA-MB-435 cells. Perfusing MDA-MB-435 cells in the
presence of anti-TF antibody almost completely abolished
the gradual decrease in tumour cell velocity (Fig. 3A), as
well as the subsequent metastatic cell arrest in microvessels
(Fig. 3C and D). Finally, we investigated whether
asialofetuin, a glycoprotein carrying multiple TF antigen
moieties, would activate microvascular endothelium in
a TF antigen-dependent manner. Pre-perfusing dura
mater with asialofetuin (1.0 mg ml−1 final concentration)
resulted in an immediate (first round of perfusion)
decrease in tumour cell velocities to below those recorded
in the fourth round of the control experiments, which
remained at these levels throughout the experiment
(Fig. 3A). The asialofetuin-mediated decrease in tumour
cell velocities was accompanied by a dramatic increase
in a fraction of slowly rolling cancer cells (Fig. 3B).
Importantly, pre-incubation of asialofetuin with anti-TF
antigen function-blocking antibody abolished completely
asialofetuin effects on metastatic cell velocities (data
not shown), proportion of rolling cells (Fig. 3B), and
metastatic cell arrest and retention in microvessels (Fig. 3E
and F). These outcomes indicate that TF antigen is
indeed a structure responsible for metastasis-associated
endothelium activation. Of note, fetuin, which is identical
to asialofetuin but has TF antigen epitopes masked
covalently with sialic acid, did not modify the kinetics of
tumour cell interactions with microvascular endothelium
(data not shown).
Endothelium activation by tumour cells and
asialofetuin is manifested by the increased cell
surface galectin-3 expression on microvessels
Previously, we reported that both asialofetuin (Glinsky
et al. 2001) and TF antigen-expressing tumour cells
(Khaldoyanidi et al. 2003) cause rapid increase in
cell surface expression of β-galactoside-binding lectin
galectin-3 on cultured endothelial cells. Subsequently,
endothelium-expressed galectin-3 acts as a binding
partner for TF antigen on cancer cells (Glinsky et al.
2001), and tumour–endothelial cell adhesion is mediated
largely by TF antigen–galectin-3 interactions (Glinsky
et al. 2001, 2003; Khaldoyanidi et al. 2003). Therefore,
we investigated next whether metastatic cancer cell and
asialofetuin effects upon well-differentiated microvessels
ex vivo modify intravascular galectin-3 levels as well. The
results of these experiments demonstrated that metastasis-
associated microvascular endothelium activation induced
by both malignant cells (Fig. 4B and C) and asialofetuin
(Fig. 4D) was manifested by a marked increase in galectin-
3 cell surface expression on microvascular endothelium.
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However, intriguingly, elevated cell surface galectin-3
expression was detectable only in selected segments of
particular microvessels (mostly precapillary arterioles
ranging from 50 µm to 100 µm in diameter), suggesting
that not all microvessels respond uniformly to TF antigen-
mediated stimuli.
This phenomena was of particular note because our
previous experiments revealed that the vast majority of
Figure 3. Cancer cells and asialofetuin activate microvascular endothelium in a TF antigen-dependent
manner
A, similar to DU-145 prostate carcinoma cells (Fig. 2), highly metastatic MDA-MB-435 breast cancer cells (open
circles), expressing elevated TF antigen levels, exhibit a gradual decrease in velocity over the course of the adhesion
experiment (each round corresponds to 30 min of perfusion). By contrast, non-metastatic MDA-MB-468 cells (open
squares), deficient in TF antigen expression, do not demonstrate such a decrease. Anti-TF antigen mAb abolishes
MDA-MB-435 decrease in average velocity (filled circles). Microvascular endothelium stimulation with asialofetuin,
a glycoprotein carrying multiple TF antigen moieties (filled squares), results in the immediate drop in MDA-MB-
435 cell velocities below the fourth round control values (open circles), accompanied by a dramatic increase in
the proportion of rolling cells (B), which was inhibited completely by anti-TF antigen mAb. C, stable adhesion of
MDA-MB-435 breast cancer cells after the fourth round of perfusion inhibited by anti-TF antigen antibody (D).
E, stable adhesion of MDA-MB-435 breast cancer cells to asialofetuin-stimulated microvasculature after the first
round of perfusion inhibited by anti-TF antigen antibody (F). Scale bar, 200 µm.
neoplastic cell adhesive interactions with microvasculature
occur in precapillary arterioles and capillaries (Glinskii
et al. 2003), and that even within the arterial
microcirculatory compartment different segments of the
same vessel exhibit differential ability to bind tumour
cells. We observed frequently multiple stably adhered
tumour cells located within relatively short segments of
precapillary arterioles, whereas the rest of the vessel as well
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as neighbouring microvessels remained free of malignant
cells (Fig. 4E). This observation suggested the existence
of endothelial ‘hot spots’ within a microcirculation of
metastasis-prone organs, which possess an enhanced
ability to bind and retain metastatic cells compared with
the rest of the microvasculature. We investigated next
whether such ‘hot spots’ harbouring multiple tumour cells
correspond to the areas of elevated intravascular galectin-3
expression. The results of these experiments (Fig. 4F and
G) showed that multiple stably adhered breast and prostate
carcinoma cells do indeed reside in microvessel segments
expressing elevated galectin-3 levels. These results
further supported the idea that metastasis-associated
endothelium activation mediated by tumour-associated
carbohydrate structures and manifested by elevated cell
surface galectin-3 expression could be important in
metastatic cell arrest in the microcirculation of target
organs.
Figure 4. Metastasis-associated endothelium activation manifested by elevated intravascular galectin-3
expression
A–D, the perfusion of dura mater microvasculature with either metastatic breast (B) or prostate (C) tumour
cells or asialofetuin (D) mediates elevated cell surface galectin-3 expression in selected segments of precapillary
arterioles compared with the control (A). Left-hand panels, green fluorescence of dura mater microvessels labelled
with acridine orange. Middle panels, red fluorescence associated with cell surface galectin-3. Right-hand panels,
superimposed images showing the association of cell surface galectin-3 expression with selected segments of
pre capillary arterioles. E–G, endothelial ‘hot spots’ correspond to areas with increased cell surface galectin-3
expression. E, endothelial ‘hot spot’ harbouring multiple metastatic breast carcinoma cells, whereas the rest of the
microvasculature is free of tumour cells. F and G, multiple breast (F) and prostate (G) carcinoma cells adhered in
precapillary arteriole segments with elevated galectin-3 expression (red fluorescence). Scale bar in A–D (shown in
D), 200 µm; E–G, 50 µm.
To determine whether cancer-associated carbohydrates
(TF antigen) would activate in a similar manner
microvascular endothelium derived from other
metastasis-prone tissues, we investigated the effects
of asialofetuin on the galectin-3 expression on HBMEC
in vitro. Similar to dura mater microvasculature, HBMEC
responded to asialofetuin treatment by a rapid and
significant increase in cell surface galectin-3 expression
(Fig. 5). The asialofetuin effect on HBMEC was inhibited
almost completely by anti-TF antigen mAb, again
emphasizing the important role for this carbohydrate
structure in metastasis-associated endothelium
activation. Of note, in these in vitro experiments
as well, only selected endothelial cells responded to
asialofetuin stimulation, suggesting that even established
endothelial cell lines preserve their heterogeneity
regarding the ability to respond to carbohydrate
stimuli.
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Discussion
According to hydrodynamic studies, Poiseuille flow in
blood vessels, characterized by a parabolic profile (Fig. 6),
forces larger particles, such as non-interacting leucocytes
or cancer cells, to the centre of the stream (Segre &
Silberberg, 1962; Lawrence & Springer, 1991). Therefore, at
a constant perfusion rate, the observed gradual reduction
in tumour cell velocity (V 1–V 2) reflects their displacement
(	) out from the centre stream toward the blood vessel wall
(Fig. 6), whereas both direct tumour cell interactions with
vascular wall and the difference in torque (T 1–T 2) acting
upon malignant cell edges located distally and proximally
to a vascular wall regulate rolling response (Lawrence &
Springer, 1991). So increasing the proprotion of cancer
cells travelling at velocities below V crit, which are likely
to be retarded by adhesive interactions with vascular wall
(Ley & Gaehtgens, 1991), reflects the gradual increase
in endothelium adhesiveness resulting from metastasis-
associated endothelium activation.
As we observe essentially horizontally positioned
microvessels, one can argue that sedimentation as a result
of gravity could affect tumour cell radial position and cause
their margination (Fig. 7A), which in turn may lead to
Figure 5. TF antigen-dependent galectin-3 cell surface
mobilization on human bone marrow microvascular
endothelium
Stimulation of human bone marrow microvascular endothelial cells
with asialofetuin resulted in a rapid (25 min) increase in cell surface
galectin-3 expression, which was almost completely abolished by
anti-TF antigen monoclonal antibody. A, transmitted light images of
the fields analysed for galectin-3-associated immunofluorescence in B.
C, quantification of the galectin-3 cell surface expression using NIH
imaging software.
Figure 6. Parabolic profile of velocity distribution in blood
vessels
A decrease in tumour cell velocity V 1 – V 2 reflects their displacement
	 from the centre of the stream toward the vascular wall, whereas
both direct tumour–endothelial cell interactions and difference in
torque T 1 – T 2 acting upon opposite tumour cell edges induce rolling
response.
Figure 7. Cancer cell interactions with vascular walls determine
their radial position and adhesive behaviour within perfused
microvasculature
Sedimentation as a result of gravity would cause tumour cell
displacement into the bottom part of a microvessel (A). Consequently,
such cells would appear under a microscope as rolling along the
centreline in a straight microvessel segment (B), or slightly deviating
from the centreline as a result of out of centre forces in an arched
microvessel (D). However, in reality, metastatic cells frequently interact
with the lateral microvessel edges as in Fig. 1, or roll along both
concave and convex vessel edges, as well as along the centreline, in
arched microvessels. Scale bar in D–F (shown in F), 50 µm.
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an increase in malignant cell adhesive interactions with
vascular wall. However, the effects of gravity (if any) would
remain the same throughout the course of the experiment,
and cannot provide a feasible rationale for the observed
gradual changes in tumour cell velocity and rolling. In
addition, sedimentation as a result of gravity would cause
neoplastic cell accumulation in the bottom portion of a
vessel lumen (Fig. 7A). If that were the case, then we would
observe interacting/rolling cells travelling mostly along the
centreline of horizontally positioned blood vessels (Fig. 7B
and C). However, in either straight or arched microvessel
segments, we often observe cancer cells interacting with
lateral ‘edges’ of the vessel wall (Figs 1 and 7D and
F). These observations are consistent with the results
on leucocyte adhesion previously reported by Firrell &
Lipowsky (1989), showing that ∼50% of rolling leucocytes
interact with lateral vessel ‘edges’ including the anterior
and posterior vessel walls. It appears that under conditions
of flow, hydrodynamic forces acting upon cancer cells
largely compensate for the effects of gravity, and similarly
to leucocyte rolling in venules (Ley & Gaehtgens, 1991),
changes in endothelial properties, not in haemodynamics,
are responsible for metastatic cell rolling in arterioles.
Nevertheless, haemodynamic factors (if present) could
contribute potentially to the overall reduction in neoplastic
cell velocities. In this study, we did not assess blood flow
velocity independent of changes in tumour cell velocities.
Therefore, we cannot completely rule out possible
haemodynamic aberrations resulting from blood vessel
reaction in response to cancer cell perfusion. However,
when TF antigen-deficient non-metastatic MDA-MB-468
cells were perfused, they did not exhibit any decrease in
velocity (Fig. 3A). Furthermore, blocking TF antigen with
mAb abrogated changes in adhesion kinetics (Fig. 3B)
and travelling velocities of highly metastatic MDA-MB-
435 cells (Fig. 3A). These results indicate clearly that even
if changes in haemodynamics took place, they were also
TF antigen-dependent, i.e. resulting from microvascular
reaction in response to TF antigen-mediated endothelial
activation.
In summary, the results of this study demonstrate
that microvascular endothelium in metastasis-prone
tissues undergoes activation in response to desialylated
cancer-associated carbohydrate structures (TF antigen)
expressed on tumour cells and glycoproteins, manifested
by cell surface mobilization ofβ-galactoside-binding lectin
galectin-3. Such activation, preceding tumour cell arrest
and retention in microcirculation, could play an important
role in haematogenous breast and prostate cancer
metastasis. The efficient inhibition of this process by anti-
TF antigen antibody suggests that metastasis-associated
endothelium activation could be an important target for
developing new approaches to cancer therapy. Of note, the
metastasis-associated endothelium activation described
here occurs in response to carbohydrate stimuli in the
absence of cytokines. To the best of our knowledge, this
is the first report describing such carbohydrate-mediated
endothelium activation. As desialylated cancer-associated
carbohydrate structures such as TF antigen could appear
under special circumstances on the surfaces of normal cells
as well (e.g. aged erythrocytes), this phenomena could also
be of general physiological significance.
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